Table 1 Multivariate analysis of factors related to overall survival in the TCGA glioma cohort
From: Antiproliferative and apoptotic effects of telmisartan in human glioma cells
Multivariate analysis | |||
|---|---|---|---|
Variable | Hazard ratio | 95% confidence interval | P Value |
Age (≥ 52, < 52) | 2.046 | 1.459–2.870 | < 0.001* |
PDGFRA expression level (high vs. low) | 1.014 | 0.747–1.376 | 0.929 |
Tumor Grade (Gr I, II, III, IV) | 2.444 | 1.875–3.185 | < 0.001* |
Sex (male vs. female) | 0.983 | 0.751–1.289 | 0.904 |
AGTR1 expression level (high vs. low) | 1.381 | 1.020–1.869 | 0.037* |
EGFR expression level (high vs. low) | 1.086 | 0.830–1.421 | 0.548 |
TERT expression level (high vs. low) | 1.231 | 0.887–1.709 | 0.214 |
ATRX expression level (high vs. low) | 0.942 | 0.709–1.252 | 0.681 |
TP53 expression level (high vs. low) | 1.096 | 0.809–1.486 | 0.553 |
MGMT expression level (high vs. low) | 1.256 | 0.941–1.677 | 0.121 |
NF1 expression level (high vs. low) | 0.678 | 0.478–0.962 | 0.029* |
NF2 expression level (high vs. low) | 0.823 | 0.596–1.137 | 0.239 |
NEFL expression level (high vs. low) | 0.927 | 0.713–1.206 | 0.572 |
AXL expression level (high vs. low) | 1.582 | 1.214–2.061 | 0.001* |
NR4A1 expression level (high vs. low) | 0.860 | 0.665–1.114 | 0.253 |